Rates of long-term major adverse cardiovascular events (CVEs) fell after the COVID-19 pandemic began in early 2020 and remained lower over the next year among commercially insured New England patients seeking care, and the incidence of congestive heart failure (CHF) and angina (chest pain) remained lower than expected.
As Covid rises again, killing about 1,500 Americans each week, medical researchers are trying to understand why so few people are taking Paxlovid, a medicine that is stunningly effective in preventing severe illness and death from the disease.
Recent Comments